Compare ZJYL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | KALA |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.7M | 319.6M |
| IPO Year | 2020 | 2017 |
| Metric | ZJYL | KALA |
|---|---|---|
| Price | $2.01 | $0.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 214.4K | ★ 8.0M |
| Earning Date | 08-20-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.15 |
| 52 Week High | $2.86 | $20.58 |
| Indicator | ZJYL | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 70.71 | 26.81 |
| Support Level | $0.57 | N/A |
| Resistance Level | $2.86 | $0.72 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 49.09 | 19.48 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.